Fecal Microbiota Transplantation for the Treatment of Diarrhea-Predominant Irritable Bowel Syndrome
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The objectives of this study are (1) to determine the efficacy of fecal microbiota
transplantation (FMT), given as oral capsules, compared with placebo for the treatment of
refractory diarrhea-predominant irritable bowel syndrome (IBS-D); (2) determine the impact of
FMT on the intestinal microbiome of patients with IBS-D; and (3) assess the safety,
feasibility, and tolerability of FMT for patients with IBS-D.